November 26, 2018
CMIC Holdings Co., Ltd.

Conclusion of the research partnership agreement with the University of Yamanashi

CMIC Holdings Co., Ltd.(Head Office: Tokyo, Minato-ku, Representative Director & CEO Kazuo Nakamura, hereafter “CMIC”)today, made the research partnership agreement with the University of Yamanashi (President: Shinji Shimada). In the health care field, CMIC and the University of Yamanashi will collaborate for training and exchange of talents for growth and for the development of local society to be affluent and dynamic.

Activities

*Talents exchange
*Utilizing mutual research facilities
*Joint research (e.g. Research on the exacerbation factor of pollen allergy in Yamanashi prefecture)

Background

In the 3rd medium-term objective and plan, the University of Yamanashi set a policy of “contribution to the local”, with the motto “Creating the Backbone of the Community and Developing Citizens of the World”. The University of Yamanashi clarifies that they actively involved with regional promotions responding to the various demands and expectation from the local areas.

In the area of healthcare, which plays an important role in regional development, the University of Yamanashi will tackle local issues and promote research that extends healthy life expectancy and leads healthy and happy lives for residents.

The CMIC Group's corporate philosophy is to continue taking on the challenge of bringing about innovation in the healthcare field. In cooperation with Yamanashi University, we will accumulate meaningful scientific data in the healthcare field and work to further extend the healthy life expectancy of local residents, thereby embodying our corporate philosophy.
 

Purpose of the partnership agreement

The objective of this Agreement is to contribute to the advancement of science and technology and human resources development in the field of healthcare through mutual cooperation between the University of Yamanashi and the CMIC Group, including research and development, education, and training in the field of healthcare.

In collaboration with the University of Yamanashi and the CMIC Group, we will conduct research, clinical trials, and other activities to collect meaningful scientific data in the healthcare field.

The University of Yamanashi draws on the research and development and clinical trial know-how of the CMIC Group to formulate clinical trial plans and develop new pharmaceuticals and medical devices. The University of Yamanashi also conducts epidemiological studies and clinical research to contribute to the development of disease prevention, diagnosis, and treatment.

On the other hand, the CMIC Group analyzes accumulated data and uses it in the development and marketing of pharmaceuticals and medical devices that are meaningful in the healthcare field.

Utilizing the resources of both parties, we will achieve innovative research results in the healthcare field, extend healthy life expectancy for local residents, and promote research that can lead healthy and happy lives.

Future outlook

Both sides will work together to resolve various problems in the healthcare field and produce research results that are useful to patients and local residents. We include from infancy to old age, and conduct surveys, research, and tests to ensure healthy and fulfilling lives and to extend healthy life expectancy. By collaborating with the University of Yamanashi, which possesses cutting-edge medical technology, and the CMIC Group, which possesses R&D know-how in the healthcare field, we will further strengthen R&D.

Execution Date

November 26, 2018

CMIC HOLDINGS Co., Ltd.

CMIC Group started business in 1992 as the first CRO in Japan, and the company today provides comprehensive support services for the development, manufacturing, sales, and marketing of pharmaceutical products. Also, the company operates to respond to diversifying needs by managing the Healthcare Business sector and developing and selling diagnostic pharmaceuticals and orphan drugs. CMIC Group has developed a unique business model called Pharmaceutical Value Creator (PVC) based on its abundant accumulated experience and knowledge as a CRO pioneer. CMIC utilizes the PVC to create new value in the healthcare field.
For more information, visit CMIC Group’s website:https://www.cmicgroup.com/e/

Inquiries

CMIC Holdings Co., Ltd. Corporate Communications Division, PR Group 
TEL:03-6779-8200 / e-mail: pr@cmic.co.jp
 

SHARE